本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/6 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 9 日~2025 9 4 | 5 | 年 | 月 | 日 | | 预计回购金额 | 15,000万元~30,000万元 | | | | | | 回购用途 | √减少注册资本 | | | | | | | □用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 354.0021万股 | | | | | | 累计已回购股数占总股本比例 | 0.5890% | | | | | | 累计已回购金额 | 15,006.9654万元 | | | | | | 实际回购价格区间 | 37.65元/股~45.14元/股 | | | | | 一、 回购股份的基本情况 甘李药业股份有 ...

北京市中伦律师事务所 关于甘李药业股份有限公司 差异化分红事项的 法律意见书 二〇二五年五月 关于甘李药业股份有限公司 差异化分红事项的 法律意见书 致：甘李药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为甘李药业股份有限公司（以 下简称"公司"）聘请的专项法律顾问，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司股份回购规则》（以下简称"《回购规则》"）、《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》（以下简称"《监管指引第 7 号》"）及《上海证券交 易所交易规则》等相关法律、行政法规、规章、规范性文件及《甘李药业股份有 限公司章程》（以下简称"《公司章程》"）的规定，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对公司 2024 年度利润分配所涉及的差异化分红（以 下简称"本次差异化分红"）相关事项所涉及的有关事实进行核查的基础上，出 具本法律意见书。 就公司提供的文件、资料和陈述，本所及本所律师已得到公司的如下保证： 1．文件上所有的签名、印鉴都是真实的； 2．所有提供给本所及本所律师的文件 ...

甘李药业股份有限公司 证券代码：603087 证券简称：甘李药业 公告编号：2025-041 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/10 | － | 2025/6/11 | 2025/6/11 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东大会审议通过。 二、 分配方案 本次利润分配以实施权益分派股权登记日登记的公司总股本 601,065,290 股为 基数，扣除回购专用账户上的股份 3,540,021 股，即以 597,525,269 股为基数，向 全体股东每股派发现金红利 1 元（含税），共计派发现金红利 597,525,269 元(含税)。 根据公司 2024 年年度股东 ...

Core Viewpoint - The announcement details the achievement of conditions for the second unlock period of the 2022 restricted stock incentive plan of Ganli Pharmaceutical, allowing 125 eligible participants to unlock a total of 1,121,760 shares [1][9][12] Summary by Sections 1. Approval and Implementation of the Incentive Plan - The incentive plan was approved on October 24, 2022, during the fourth board meeting, with independent directors expressing agreement [2] - The list of incentive objects was disclosed on October 25, 2022, and no objections were raised during the public notice period [2] - The first extraordinary general meeting of shareholders approved the plan on November 15, 2022 [2] - Adjustments to the incentive object list were made on November 28, 2022, with independent directors and the supervisory board agreeing [3] 2. Conditions for Unlocking Shares - The second unlock period has been reached, with the unlock conditions specified in the incentive plan [4] - The second unlock period conditions include no negative audit opinions on financial reports and no disqualifications of incentive objects [5][6][7] - The company achieved a net profit of 6.15 billion for the 2024 fiscal year, exceeding the required 6 billion, thus meeting the performance criteria for the second unlock period [9] 3. Specifics of the Unlocking Process - A total of 112.176 million shares will be unlocked, representing 29.98% of the total granted shares [4][11] - The unlocking procedures will be completed after the 2024 profit distribution, with a subsequent announcement to investors [4] - The incentive plan allows for annual assessments of the incentive objects, determining the proportion of shares that can be unlocked based on individual performance [8][10] 4. Opinions from Committees - The Compensation and Assessment Committee confirmed that the conditions for the second unlock period have been met and that the 125 eligible participants are legally qualified [9] - The supervisory board also agreed that the conditions for unlocking shares are in compliance with relevant regulations and the incentive plan [10]

Core Viewpoint - 甘李药业 announced the repurchase and cancellation of certain restricted stocks from its 2022 and 2024 incentive plans, along with adjustments to the repurchase prices [1][10]. Group 1: Repurchase Details - The number of restricted stocks to be repurchased under the 2022 incentive plan is 169,300 shares [1][7]. - The number of restricted stocks to be repurchased under the 2024 incentive plan is 72,000 shares [1][7]. - The repurchase price for the 2022 incentive plan is set at 15.65 yuan per share [1][8]. - The repurchase price for the 2024 incentive plan is set at 18.09 yuan per share [1][8]. Group 2: Reasons for Repurchase - The repurchase is due to 10 individuals from the 2022 incentive plan leaving the company, leading to the cancellation of their stock qualifications [7]. - One individual from the 2024 incentive plan also left, prompting the cancellation of their stock qualifications [7]. - Performance evaluations for some individuals resulted in partial stock repurchases due to unmet performance criteria [7]. Group 3: Impact on Share Structure - After the repurchase, the proportion of restricted shares will be 7.84%, while unrestricted shares will remain at 92.16% [9]. - The total number of shares will decrease from 600,823,990 to 601,065,290 shares post-repurchase [9]. - The repurchase will not change the controlling shareholder or the actual controller of the company [9]. Group 4: Financial Impact - The repurchase of restricted stocks is not expected to have a substantial impact on the company's financial status or operational results [10]. - The management team will continue to fulfill their responsibilities diligently, aiming to create value for shareholders [10]. Group 5: Approval and Legal Compliance - The repurchase plan has been approved by the company's board and supervisory committee [10]. - The funding for the repurchase will come entirely from the company's own funds [10]. - The legal opinions confirm that the repurchase complies with relevant laws and regulations [11].

Core Viewpoint - 甘李药业 announced a change in its registered capital and a revision of its articles of association due to the repurchase and cancellation of certain restricted stocks that no longer meet incentive conditions [1][2][3] Summary by Sections Reason for Modification - The company will repurchase and cancel a total of 241,300 restricted stocks that have not met the incentive conditions, leading to a reduction in total share capital and registered capital [1][2] Changes in Registered Capital and Articles of Association - After the repurchase, the total share capital will decrease from 601,065,290 shares to 600,823,990 shares, and the registered capital will change from 601,065,290 yuan to 600,823,990 yuan [2] - The specific revisions to the articles of association include: - Article 6: Registered capital will be revised from 60,106.529 million yuan to 60,082.399 million yuan - Article 20: Total number of shares will be revised from 60,106.529 million shares to 60,082.399 million shares [2][3] Other Provisions - Other contents of the articles of association remain unchanged, and the changes will be finalized upon approval by the relevant market supervision authorities [3] - The company has followed the necessary procedures to notify creditors, who have the right to request debt repayment or guarantees within specified timeframes [3]

Core Viewpoint - The legal opinion letter addresses the conditions for the lifting of restrictions on the stock incentive plans of Ganli Pharmaceutical Co., Ltd. for 2022 and 2024, confirming that the necessary approvals and authorizations have been obtained for the lifting of restrictions, stock repurchase, and price adjustments [1][26]. Summary by Sections Legal Framework - The legal opinion is based on the Company Law, Securities Law, and relevant regulations from the China Securities Regulatory Commission [3][4]. - The law firm conducted thorough verification of documents and facts related to the stock incentive plans [2][3]. 2022 Stock Incentive Plan - The second lifting of restrictions for the 2022 plan allows for 30% of the total granted restricted stocks to be released after 24 months from the registration date [12][17]. - The registration date for the 2022 plan was December 20, 2022, and the second lifting period ended on December 23, 2024 [13][17]. - A total of 125 individuals are eligible for the lifting of restrictions, with 1,121,760 shares (0.19% of total shares) available for release [17][26]. 2024 Stock Incentive Plan - The first lifting of restrictions for the 2024 plan allows for 30% of the total granted restricted stocks to be released after 12 months from the registration date [17][22]. - The registration date for the 2024 plan is May 24, 2024, with the first lifting period ending on May 26, 2025 [17][22]. - A total of 86 individuals are eligible for the lifting of restrictions, with 2,103,000 shares (0.35% of total shares) available for release [22][26]. Stock Repurchase and Price Adjustment - The company plans to repurchase and cancel restricted stocks for 14 individuals due to their departure or performance results [23][24]. - The repurchase price for the 2022 plan is adjusted to 15.65 CNY per share, and for the 2024 plan, it is adjusted to 18.09 CNY per share [23][25]. - The adjustments comply with the relevant regulations and do not require further shareholder approval [25][26]. Conclusion - The legal opinion confirms that all actions regarding the lifting of restrictions, stock repurchase, and price adjustments are in compliance with applicable laws and regulations [26].

Summary of Key Points Core Viewpoint - Ganli Pharmaceutical Co., Ltd. announced the repurchase and cancellation of a portion of restricted stock, notifying creditors about the implications of this action [1][2]. Repurchase and Cancellation Reasons - On May 30, 2025, Ganli Pharmaceutical's board and supervisory board approved the repurchase and cancellation of 241,300 shares of restricted stock that no longer meet the incentive conditions, as per the company's 2022 and 2024 restricted stock incentive plans [2]. - Following the repurchase, the company's registered capital will decrease from 601,065,290 yuan to 600,823,990 yuan, a reduction of 241,300 yuan [2]. Creditor Information - The repurchase and cancellation will lead to a reduction in the company's registered capital, necessitating notification to creditors as per the Company Law of the People's Republic of China [3]. - Creditors have 30 days from the notification date, or 45 days from the announcement date if not notified, to claim their debts or request guarantees [3]. - Required documentation for debt claims includes valid debt documents and identification, with specific requirements for both corporate and individual creditors [3].

证券代码：603087 证券简称：甘李药业 公告编号：2025-038 1 2022 年限制性股票激励计划限制性股票回购数量：16.93 万股； 2024 年限制性股票激励计划限制性股票回购数量：7.2 万股； 2022 年限制性股票激励计划限制性股票回购价格：15.65 元/股。 2024 年限制性股票激励计划限制性股票回购价格：18.09 元/股。 甘李药业股份有限公司 关于回购注销部分限制性股票并调整回购价格的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 甘李药业股份有限公司（以下简称"公司"）于 2025 年 5 月 30 日分别召开 第五届董事会第一次会议、第五届监事会第一次会议，审议通过了《关于回购注 销部分限制性股票并调整回购价格的议案》。根据《公司 2022 年限制性股票激励 计划（草案）》及其修订稿（以下简称"《2022 年激励计划（草案）》"）、《公司 2024 年限制性股票激励计划（草案）》及其修订稿（以下简称"《2024 年激励计划（草 案）》"）的规定，现就公司 2022 年 ...

一、通知债权人的原由 甘李药业股份有限公司（以下简称"公司"）于 2025 年 5 月 30 日召开第五 届董事会第一次会议和第五届监事会第一次会议，审议通过了《关于回购注销部 分限制性股票并调整回购价格的议案》。根据公司《2022 年限制性股票激励计划 （草案）》及其修订稿、《2024 年限制性股票激励计划（草案）》及其修订稿的相 关规定，公司将回购注销已不符合激励条件的激励对象已获授但尚未解除限售的 限制性股票合计 241,300 股。具体内容详见公司于 2025 年 5 月 31 日披露的《甘 李药业股份有限公司关于回购注销部分限制性股票并调整回购价格的公告》（公 告编号：2025-038）。回购完毕后，公司将向中国证券登记结算有限责任公司上 海分公司申请注销该部分股票，注销完成后，公司的注册资本由 601,065,290 元 减少为 600,823,990 元。 二、需债权人知晓的相关信息 由于公司本次回购注销部分限制性股票将减少公司注册资本，依据《中华人 民共和国公司法》等相关法律、法规的规定，公司特此通知债权人，债权人自接 到公司通知之日起 30 日内、未接到通知者自本公告披露之日起 45 日内， ...